New research from the Smidt Heart Institute at Cedars-Sinai found that women who developed signs of elevated blood pressure during pregnancy were more likely to have residual evidence of abnormal heart structure and function up to a decade after the pregnancy.
MSD’s Keytruda expands reach in lung cancer with neoadjuvant setting approval – Pharmaceutical Technology
Merck’s Keytruda (pembrolizumab) and chemotherapy combo is indicated to treat resectable NSCLC. Credit: © 2023 Merck & Co., Inc., Rahway, NJ USA, and its affiliates.
October 17, 2023